Background: We previously demonstrated in mice that airway eosinophils traffic from the airway lumen into lung-draining paratracheal lymph nodes. However, mechanisms whereby eosinophils traverse from the lungs and home to paratracheal lymph nodes remain unclear. We investigated roles of cysteinyl leukotrienes in mediating eosinophil trafficking from lungs to paratracheal lymph nodes. Methods: The expression of CCR7 was determined by flow cytometry. Transwell assays were used to test chemotactic responses of leukotriene C 4 synthase-deficient and control airway eosinophils to the chemokine CCL19 ex vivo. Eosinophils from the spleens of IL-5 transgenic mice, fluorescently labeled ex vivo, were intratracheally injected into ovalbumin-sensitized and ovalbumin aerosol-challenged leukotriene C 4 synthase-deficient and control mice. Eosinophils were identified by microscopy and flow cytometry in the lungs and paratracheal lymph nodes. Results: Mouse eosinophils expressed CCR7, the receptor for CCL19, and responded chemotactically to CCL19. Leukotriene C 4 synthase-deficient eosinophils exhibited impaired chemotaxis to CCL19 that was restored by exogenous leukotriene C 4 . The migration of intratracheally injected eosinophils into paratracheal lymph nodes from distal alveolar lung was diminished in leukotriene C 4 synthase-deficient mice compared with wild-type mice, with increased retention of eosinophils in the lungs of leukotriene C 4 synthase-deficient mice. Exogenous administration of leukotriene C 4 restored trafficking of eosinophils to paratracheal lymph nodes in leukotriene C 4 synthase-deficient mice. Conclusions: Our findings that cysteinyl leukotrienes are involved in regulating airway and lung eosinophil migration into paratracheal lymph nodes identify previously unrecognized roles for the cysteinyl leukotrienes in regulating the pulmonary trafficking of eosinophils in experimental allergic asthma.
Eosinophils and cysteinyl leukotrienes (cysLTs) both have varied and multiple roles in mediating allergic inflammation, especially in the lung and in asthma. The cysLTs, LTC 4 , and its extracellular derivatives, LTD 4 and LTE 4 , are potent bronchoconstrictors, augment mucus release, and enhance endothelial vascular permeability (1, 2) . Within the lung, eosinophils as well as other cells are sources of cysLTs (1) . CysLTs can have varied functions on eosinophils, ranging from intracrine regulators of secretion of granule-derived proteins, including the cytokine, IL-4, to paracrine roles in eosinophil chemotaxis and recruitment (2, 3) .
In mouse models of asthma, eosinophils are recruited into the airways and lung tissues (4) . Eosinophils in the lungs in mouse models traffic from the lung into regional paratracheal lymph nodes (pLNs) (5) (6) (7) . Several studies have demonstrated that migrating lung eosinophils can function as 'professional' antigen-presenting cells (APCs). Eosinophils exposed to airways antigens can internalize, process, and directly present antigens, and requisite eosinophil lysosomal antigen processing can be blocked by inhibitors of lysosomal acidification (including NH 4 Cl for erythrocyte lysis), either employed incidentally (8) or more formally studied (7) . In mice, lung-derived and migrated eosinophils in the pLN express MHC class II and costimulatory proteins (CD40, CD80, CD86) and in antigen-specific fashions elicit TH2-biased responses with elicited secretion of TH2 cytokines (5, 7) . Within pLN, lung-recruited eosinophils localize to T-cellrich paracortical areas (5-7) and have been visualized directly interacting with antigen-specific T cells within pLN (5, 7) . A recent study of human pLN and large airways in patients with fatal asthma now has provided fully comparable findings for humans (9) .
Little is known about the trafficking of eosinophils to pLN. Studies in mice have demonstrated identical trafficking of intratracheally instilled eosinophils to pLN in both normal, unsensitized mice and Ag-sensitized, airway Agchallenged mice (6) . Eosinophil trafficking to pLN is not dependent on chemokines acting via CCR3 (6) or acting via CCR1 (Wang and Weller, unpublished) as eosinophils genetically deleted of these receptors migrated equally into pLN. Hence, eosinophil trafficking is not likely over bronchial airways walls, but rather from eosinophils in more distal alveolar spaces (6) . Lung emigrating mouse eosinophils have been imaged within lymphatic vessels (5). Alveolar, peripheral localizations of eosinophils are recognized in human asthma (10, 11) and leukotriene C 4 synthase has been localized in the peripheral alveolar regions (12) . Mobilization from alveolar spaces into draining lymphatic vessels might be by varied peripheral lymphatic structures, likely not fully defined morphologically and of uncertain function (13, 14) . The chemokine receptor CCR7 on APCs and its chemokine ligands, CCL19 and CCL21, have central roles in orchestrating the movement of canonical APCs into proximate interactions with CD4 + lymphocytes in lymph nodes (15) . We have previously demonstrated that human eosinophils express functional CCR7 and have multiple functional responses, including chemotaxis, to CCL19 and CCL21 (16) . Host-derived cysLTs may critically regulate the migration of immune cells. The migration of dendritic cells from the skin to lymph nodes was shown to be dependent on cysLTs, based on studies of mice genetically deficient in multidrug resistance-associated protein-1 (MRP1) that is required for the extracellular secretion of LTC 4 (17) . LTC 4 promotes chemotaxis of skin epidermal dendritic cells to the chemokine CCL19 in mice, and such was blocked in MRP1 À/À mice that could not secrete formed LTC 4 , but was restored by exogenous cysLTs (17) . In contrast, lung dendritic cells that used CCR7 ligands to migrate to pLN were not dependent on cysLTs, as assessed with MRP1
À/À mice (18) .
In the present study, we aimed to ascertain whether and how host-derived cysLTs alter the migrations of native mouse eosinophils, who retain the capacity to secrete LTC 4 , as they egress from the lungs to pLNs.
Material and methods

Mice
LTC 4 S
À/À mice and wild-type (LTC 4 S +/+ ) littermate controls on a BALB/c background were originally generated as described (19) . IL-5 transgenic BALB/c mice heterozygous for a transgene that expresses murine IL-5 under the control of human CD2 regulatory sequences (20) were obtained courtesy of Dr. Craig Gerard (Boston Children's Hospital). Protocols used were approved by the Institutional Animal Care and Use Committee at Beth Israel Deaconess Medical Center.
Antibodies and reagents
Mouse anti-CD19 and anti-CD90 magnetic microbeads were used in eosinophil purification (Miltenyi Biotec, San Diego, CA, USA). Ovalbumin (OVA; Sigma-Aldrich, St. Louis, MO, USA) and alum adjuvant (Thermo Scientific, Rockford, IL, USA) was used in allergen sensitization and challenge. Allophycocyanin-and phycoerythrin-labeled anti-mouse CCR7 antibodies (Clone 4B12) were from BioLegend (San Diego, CA, USA). Rabbit polyclonal anti-CysLT1 antibody was from Dr. Yoshihide Kanaoka. Anti-mouse CD11a, CD18, and a4b7 were from BioLegend.
Eosinophil isolation from spleens of IL-5 transgenic mice
Single-cell suspensions were made from spleens of IL-5 transgenic mice. Eosinophils were isolated from single-cell suspensions by negative selection as previously described (6) . Purity was routinely >98% as assessed by Hema 3 staining. Viability was routinely >98% by trypan blue exclusion.
Flow cytometry and microscopy
The flow cytometer used was a BD Biosciences FACScan. FlowJo (TreeStar, Ashland, OR, USA) was used for data analysis. Microscopy was performed using a motorized Olympus BX62 fluorescence microscope. To visualize fluorescently labeled eosinophils, OCT-frozen pLNs were cryosectioned (5-lm-thick sections) and collected onto Superfrost slides. Images were acquired using bandpass zero-shift TRITC and DAPI filters and overlapped using IpLab 3.6 (BD Biosciences, San Jose, CA, USA).
Expression of cysLT receptors on mouse eosinophils by reverse transcription polymerase chain reaction (RT-PCR)
Total RNA was isolated from purified eosinophils or lungs of wild-type mice using commercially available kits (Qiagen, Germantown, MD, USA For relevant experiments, isolated eosinophils in phosphatebuffered saline (PBS) were labeled ex vivo with the plasma membrane inserted cell tracker red-orange fluorescent dye, (3)) (Life Technologies, Grand Island, NY, USA), by incubating at 37°C for 15 min. Viability of eosinophils after ex vivo labeling was routinely >98%. Two hours before, the last OVA aerosol challenge in OVA-sensitized, OVA-challenged mice on Day 23, 1 9 10 6 fluorescently labeled eosinophils were instilled by intratracheal injection.
For relevant experiments, LTC 4 in PBS (1 lg/animal; Cayman Chemical, Ann Arbor, MI, USA) was administered by intratracheal injection 2 h after the second OVA challenge on Day 22.
Chemotaxis assays
Eosinophils, purified from BAL fluid of OVA-sensitized and OVA-challenged wild-type or LTC 4 S À/À mice, were resuspended at a concentration of 1 9 10 6 cells/ml in RPMI 1640 with 0.1% OVA, 24 mM HEPES, and 2 mM glutamine and pre-incubated for 30 min with LTC 4 (200 nM) or control medium. Transwell permeable supports containing polycarbonate membranes with 5-lm pores were used (Corning, Lowell, MA, USA). The lower chambers below the transwell contained 600 ll of RPMI-1640 containing 0.2% bovine serum albumin with or without recombinant CCL19 or CCL21 (R&D Systems, Minneapolis, MN, USA) or sphingosine-1-phosphate (Sigma). Eosinophil suspensions (100 ll) were added to the upper chamber. Wells were set up in triplicate for each experiment. Chemotaxis plates were incubated at 37°C for 2 h. Migrating cells in the lower chamber were counted for 15 s in triplicate by flow cytometry.
Eosinophil isolation from bronchoalveolar lavage
The lungs were lavaged four times with 1 mL aliquots of PBS containing 4 mM EDTA to obtain BAL. Eosinophils were purified on discontinuous Percoll density gradients followed by immunomagnetic purification as previously described (MACS; Miltenyi Biotec) (6).
Statistical analyses
Unpaired t-tests were used where indicated for analysis of flow cytometry data with the level of significance set at P < 0.05. Data are expressed as mean AE SD.
Results
Murine eosinophils express the leukotriene receptors CysLT 1 and CysLT 2 and the chemokine receptor CCR7
We have demonstrated functional effects of cysteinyl leukotrienes on the secretory capacities of human eosinophils (6, 7) . In the present work, we first sought to demonstrate that mouse eosinophils express the cysteinyl leukotriene receptors, (Fig. 1B and C) . We have also shown that human eosinophils express the chemokine receptor CCR7, which has a central role in coordinating leukocyte trafficking from tissues to lymph nodes, including from the lungs into mediastinal lymph nodes (16) . We sought here to establish that mouse eosinophils express CCR7 as well. Eosinophils isolated from spleens of IL-5 transgenic mice were assessed by flow cytometry for the presence of CCR7, the receptor for CCL19. CCR7 was present on the surface of eosinophils (Fig. 1D) . These data are representative of three independent experiments. Exogenous administration of LTC 4 with concentrations up to 200 nM did not alter the surface or total intracellular expression of CCR7 by eosinophils isolated from the spleens of IL-5 transgenic mice, from the BAL of OVA-sensitized and OVA-challenged mice, and from the BAL of OVA-sensitized and OVA-challenged LTC 4 S À/À mice (Fig. S1 ). Eosinophils isolated from the BAL of OVA-sensitized and OVA-challenged wild-type and LTC 4 S À/À mice also demonstrated surface expression of CCR7 ( Fig. 1E and F) . There was no difference between wild-type and LTC 4 S À/À mice in the surface expression by BAL eosinophils of the adhesion molecules CD11a, CD18, and a4b7 (Fig. S2) .
Full in vitro migratory capacity of eosinophils to CCL19 is dependent on LTC 4
Transwell assays were performed to assess chemotaxis of isolated lung eosinophils from OVA-sensitized and OVA- ) mice are incapable of synthesizing LTC 4 due to the lack of this enzyme. Chemotaxis to CCL19 was robust in wild-type lung eosinophils, without any further augmentation when eosinophils were pretreated with exogenous LTC 4 prior to chemotaxis assays. Lung eosinophils from LTC 4 S À/À eosinophils, however, displayed substantially reduced chemotaxis to CCL19 that was almost fully restored when they were pretreated with LTC 4 prior to chemotaxis assays ( Fig. 2A) . The results are compiled from two independent experiments. The restoration of impaired chemotaxis to CCL19 with LTC 4 pretreatment was observed across all concentrations of CCL19 that were tested (Fig. 2B) . We also tested chemotaxis to CCL21, the other known ligand of CCR7, and did not observe differences in migration to CCL21 between wild-type and LTC 4 S À/À BAL eosinophils at the concentrations tested (Fig. S3) . We did not observe migration by wild-type or LTC 4 S À/À eosinophils to S1P, a lipid mediator involved in immune cell trafficking (Fig. S4) . (Fig. 3A) . We previously used a similar model of allergic airway inflammation with intratracheal adoptive transfer of fluorescent eosinophils to demonstrate that eosinophils migrate to pLN, where they interact with CD4 + lymphocytes and act as antigen-presenting cells (7) . Intratracheal instillation of PBS alone served as a control. Twenty-four hours after the last OVA challenge, (Fig. 3C ). Aggregate data from six mice per group over three separate experiments show this decrease in DiIC 16 (3)-labeled eosinophils to the pLN to be a consistent finding (P < 0.01; Fig. 3D ).
To visualize dynamics of eosinophil egress from lungs, we adoptively transferred fluorescently DiIC 16 (3)-labeled eosinophils into the lungs of wild-type host mice. We observed that the fluorescently labeled eosinophils in lungs decreased quickly over time (Fig. 4A) . To quantify the fluorescently labeled eosinophils in lungs, we made single-cell suspensions from lungs of host mice harvested at various time points after the last OVA inhalation challenge, and assessed by flow cytometry to determine the kinetics of fluorescently labeled eosinophil egress from the lungs. We compared 24-and 72-hour time points in wild-type and LTC4S-/-mice to determine whether the decrease in eosinophil trafficking to draining pLN of LTC 4 S À/À mice correlated with increased numbers of eosinophils in the lungs (Fig. 4B) 4 had partial restoration of eosinophil migration to draining paratracheal lymph nodes at the dose used (Fig. 5B ). Aggregate data from four mice per group over two separate experiments are displayed in Fig. 5C .
Discussion
The data presented here build upon our prior observations in mouse models of allergic airway inflammation that eosinophils migrate from lung to pLN and interact with CD4 + lymphocytes (6, 7). We establish that mouse eosinophils express CCR7, which is the ligand for CCL19 and a key factor in leukocyte migration to lymph nodes, and also express CysLT 1 and CysLT 2 , the appropriate receptors for LTC 4 . Our observations of in vitro chemotactic behaviors to CCL19 of eosinophils from LTC 4 synthase-deficient animals indicate that LTC 4 has a direct effect in facilitating chemotaxis, as pre-incubation of these eosinophils with LTC 4 restores their full chemotactic potential to CCL19. Furthermore, the restoration of chemotactic activity to eosinophils that cannot produce their own LTC 4 suggests the possibility of a paracrine effect by LTC 4 in augmenting chemotaxis. We observed in vivo that eosinophil migration to the paratracheal lymph nodes is substantially diminished in mice lacking LTC 4 synthase undergoing an OVA sensitization and OVA challenge model of asthma, compared with wild-type controls. Furthermore, eosinophils are retained in the lungs of mice devoid of LTC 4 due to the absence of LTC 4 synthase. These data indicate that egress of eosinophils from the lungs to lymph nodes is dependent on the presence of LTC 4 in the local environment. Furthermore, migration of eosinophils out of the lungs can be at least partially restored when exogenous LTC 4 is reintroduced via the airways. Dissimilar to in vitro chemotaxis experiments, the intratracheally transferred eosinophils in both LTC 4 OVA-challenged mice to restore eosinophil migration, when accounting for the relatively small cell numbers distributed over an otherwise LTC 4 -deficient cellular milieu. While these in vivo experiments do not fully delineate the mechanism by which the presence of LTC 4 facilitates the movement of eosinophils from lung to lymph node, the in vitro data presented suggest that augmentation of eosinophil chemotaxis to CCL19 is a significant contributor. Leukotrienes have long been recognized to have an integral role in allergic airway inflammation and eosinophil immunobiology (1, 22) . CysLTs have paracrine effects on eosinophil chemotaxis and recruitment, as well as regulatory function in the secretion of stored cytokine products by eosinophils (1-3) . CysLTs are important mediators in the airway inflammation, mucous production, and bronchial hyper-reactivity characteristic of asthma (23) . Mice with augmented cysLT production through the overexpression of LTC 4 S exhibit a phenotype that models human aspirin-exacerbated respiratory disease (24) . Leukotriene receptor blockade, specifically of CysLT 1 , has become a staple of asthma management (1, (25) (26) (27) . In a murine model of chronic asthma, the CysLT 1 receptor antagonist montelukast effectively reversed airway remodeling compared with corticosteroids (28) .
Exposure to lipid mediators, including leukotrienes, has been demonstrated to modulate immune cell migration (29) . Lipid mediators have specifically been observed to influence the migration of dendritic cells toward CCL19 and CCL21, the known chemokine ligands of CCR7. The CCR7 axis has an integral role in directing leukocyte movement into draining lymph nodes (15) . Prostaglandin E 2 (PGE 2 ) enhances chemotaxis of dendritic cells in response to CCR7 ligands, as well promoting CCR7 surface expression on dendritic cells and signaling through CCR7 (30) (31) (32) (33) . The interplay between lipid mediators and CCR7 function in dendritic cells extends to leukotrienes. Leukotriene B 4 is a promoter of chemotaxis and CCR7 expression in murine dendritic cells (34) . Relevant to our current findings with respect to eosinophil migration, the presence of LTC 4 with dendritic cells leads to increased stimulation of in vitro lymphocyte responses compared with PGE 2 and improved migration of dendritic cells to CCL19 (17, 35) . While the presence of CCR7 on mouse eosinophils had not been described prior to the current report, we have previously demonstrated that human eosinophils isolated from the peripheral blood and cultured in IL-5 do express CCR7 (16) . Furthermore, the expression of CCR7 is functionally significant, with eosinophils showing directed chemotaxis to CCL19 and CCL21 in a dose-dependent fashion with concomitant activation of downstream signaling pathways upon stimulation of CCR7 (16) . Our current data extend these observations to an in vivo murine model of allergic airway inflammation, while also integrating previous lines of evidence described above that suggest the integral importance of lipid mediators, specifically LTC 4 , in the responses of leukocytes to CCR7. These data also build on the recognition that eosinophils traffic to the T-cell-rich paracortical areas of draining lymph nodes in allergic airway inflammation, where they display immunoregulatory capacities, including the ability to function as antigen-presenting cells (6, 7, 21, 36) . Eosinophils also have the ability to differentially and rapidly secrete multiple preformed Th1 and Th2 cytokines to discrete stimuli, further bolstering the possibility that they may have as yet unrecognized immunoregulatory function at the level of lymph node in allergic airways disease (37) . The present findings demonstrate that LTC 4 is necessary for optimal egress of lung eosinophils to draining mediastinal lymph nodes and that LTC 4 is needed for optimal chemotaxis of eosinophils to CCL19. Distal lymphatics may play an important function as the site of egress from the lung parenchyma, although further investigation is required (38) . While our data suggest that CCR7 is central to the migration of eosinophils from lung to lymph node, there remains the possibility that CCR7 is not the only chemokine receptor that participates in the migration of eosinophils from lung to lymph node. Of note, CCR7
À/À mice that have undergone OVA sensitization and challenge do show migration of eosinophils to draining lymph nodes (39) . As eosinophils are themselves a major source of LTC 4 , there may be a significant autocrine component to the effect of LTC 4 on eosinophil migration to the draining lymph node. In our experimental model, the fluorescent eosinophils from IL-5 transgenic mice that were adoptively transferred to wild-type and LTC 4 S À/À mice were likely insufficient in number in the inflamed lung to provide enough LTC 4 to restore directed chemotaxis out of the lung. This was supported by the proportionally small number of fluorescent eosinophils that ultimately were recovered from the paratracheal lymph nodes even in wild-type mice (3.34%; Fig. 3C ).
In the aggregate, these data add to the understanding of the eosinophil trafficking from the lungs to draining lymph nodes in allergic asthma, as well as the functional importance 
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